SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2017

Investments as of December 31, 2017 and 2016 consisted of the following:



	2017		2016

Available-for-sale equity securities	$	2	$	3
Trading equity securities	58		51
Other investments	9		6
Total	$	69	$	60

Schedule of New Accounting Pronouncements and Changes in Accounting Principles

Based on the Company's assessment of this ASU, the majority of the amounts that were historically classified as bad debt expense, primarily related to patient responsibility, will be considered an implicit price concession in determining net revenues. Accordingly, the Company will report uncollectible balances associated with patient responsibility as a reduction of the transaction price and therefore as a reduction in net revenues when historically these amounts were classified as bad debt expense within selling, general and administrative expenses. As a result of this change, the Company preliminarily estimates the following impact to its consolidated statements of operations for the years ended December 31, 2017 and 2016:



	Year Ended December 31, 2017							Year Ended December 31, 2016
	As Reported		Adjustment for ASU on Revenue Recognition			As Adjusted		As Reported		Adjustment for ASU on Revenue Recognition			As Adjusted
Net revenues	$	7,709	$	(307	)	$	7,402	$	7,515	$	(301	)	$	7,214
Selling, general and administrative expenses	$	1,750	$	(307	)	$	1,443	$	1,681	$	(301	)	$	1,380
Net income attributable to Quest Diagnostics	$	772	$	—		$	772	$	645	$	—		$	645